Biological targeted treatment of refractory / relapsed diffuse large B-cell lymphoma

VernacularTitle:复发难治性弥漫大B细胞淋巴瘤的生物靶向治疗
Author: Ning LIU
Publication Type:Journal Article
Keywords: Lymphoma,large B-cell,diffuse; Relapsed; Refractory
From: Journal of Leukemia & Lymphoma 2016;25(5):317-320
CountryChina
Language:Chinese
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the aggressive non-Hodgkin's lymphoma.Rituximab in combination with chemotherapy had improved the outcomes,however,a substantial proportion of these patients transfer into refractory or eventually relapsed lymphoma after using R-CHOP as a front-line treatment regimen with poor prognosis.With the research development on DLBCL and its related gene,it is confirmed that gene biological targeted therapy can improve the prognosis of patients with refractory /relapsed DLBCL (RR-DLBCL).Recently,some new targeted therapies become research hotspots.This review will focus on recent development and future direction of biological targeted treatment in RR-DLBCL.